Silexion Therapeutics ( ($SLXN) ) has provided an update. On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received ...

Toll-like receptors (TLRs) and their signalling pathways have therapeutic potential for the treatment of inflammation, cancer, infection, allergy and autoimmunity. The elucidation of the structure ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...